Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells

Prostate

Volumn 53, Issue 1, 2002, Pages 88-94

  Medeiros, Rui ^a   Morais, Antonio ^a   Vasconcelos, André ^a   Costa, Sandra ^a   Pinto, Daniela ^a   Oliveira, Jorge ^a   Carvalho, Rodrigo ^a   Lopes, Carlos ^a  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

Author keywords

Cancer risk; Genotyping; Micrometastasis; PCR; Polymorphism; Prostate cancer; Prostate specific antigen

Indexed keywords

ANDROGEN; DNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; DNA PRIMERS; DNA, NEOPLASM; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037106039     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10135     Document Type: Article

References (27)

1. Prostate specific antigen: Biochemistry, analytical methods and clinical application
2. Clinical and molecular techniques for diagnosis and monitoring of prostatic cancer
3. Longitudinal screening of prostate cancer with prostate specific antigen
4. Susceptibility to prostate cancer: Interaction between genotypes at the androgen receptor and prostate-specific antigen loci
5. Novel polymorphisms of prostate-specific antigen (PSA) gene associated with PSA mRNA expression in breast cancer
6. Novel polymorphisms in prostate specific antigen gene and its association with prostate cancer
7. Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort
8. Detection of hematogenous micrometastasis in patients with prostate cancer
9. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: Comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays
10. Circulating prostate specific antigen positive cells correlate with metastatic prostate cancer
11. Review: Polymerase chain reaction detection of micrometastases and circulating tumor cells: Application to melanoma, prostate and thyroid carcinomas
12. Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: Implications for the detection of hematogenous prostate cells and standardization
13. Detection and clinical importance of micrometastatic disease
14. A simple salting out procedure for extracting DNA from human nucleated cells
15. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
16. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
17. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters
18. Prostate-specific antigen is regulated by an upstream enhancer
19. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter
20. Neoplasms of the prostate gland
21. Endocrine treatment of prostate cancer
22. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion
23. Mitogenic response of osteoblast cells to prostate-specific antigen suggest an activation of latent TGF-β and a proteolytic modulation of cell adhesion receptors
24. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northernblot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies
25. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue
26. Prostate-specific antigen levels and subsequent prostate cancer: Potential for screening